GENESIS Pharma, a prominent biopharmaceutical company operating in Europe, has recently entered into an exclusive distribution agreement with Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical firm dedicated to discovering and delivering innovative cancer treatments. This agreement aims to commercialize RIPRETINIB, a vital medication for patients with gastrointestinal stromal tumors (GIST), in 14 European markets within Central and Eastern Europe.
Under the terms of this exclusive distribution agreement, GENESIS Pharma will take on the responsibility of exclusively marketing and distributing RIPRETINIB across a range of Central and Eastern European countries. These countries include Bulgaria, Croatia, Cyprus, the Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia.
EU Approval Marks Milestone for RIPRETINIB in Advanced Cancer Treatment
RIPRETINIB has received approval from the European Union for the treatment of advanced gastrointestinal stromal tumors (GIST) in adult patients who have previously undergone treatment with three or more kinase inhibitors, including imatinib.
Margarida Duarte, Senior Vice President and Head of International at Deciphera Pharmaceuticals expressed excitement about the partnership, highlighting its goal to make RIPRETINIB accessible to fourth-line GIST patients across Central and Eastern Europe. Duarte emphasized Deciphera’s commitment to the global distribution of RIPRETINIB and their collaboration with GENESIS Pharma to enhance the lives of GIST patients.
Constantinos Evripides, Managing Director of GENESIS Pharma, shared his enthusiasm for expanding their network of international partners and the mutual recognition of their expertise and experience in commercializing innovative biopharmaceutical products designed to treat severe and rare diseases. This agreement reflects GENESIS Pharma’s commitment to providing access to cutting-edge cancer treatments for eligible patients across Central and Eastern Europe.
Pioneering New Hope in Gastrointestinal Stromal Tumor Treatment with RIPRETINIB
Gastrointestinal stromal tumor (GIST) is a rare neoplasm that primarily affects the gastrointestinal tract or nearby structures in the abdominal region, most commonly in the stomach or small intestine. GIST represents the most frequent type of sarcoma in the gastrointestinal tract, with an estimated annual incidence of 10-15 cases per million. The majority of GISTs are driven by specific oncogenic protein kinases, primarily KIT and PDGFRA mutations. Current therapies struggle to inhibit the entire range of primary and secondary mutations, leading to resistance to most tyrosine kinase inhibitors (TKIs) and disease progression. Depending on the disease’s stage at diagnosis, estimates for a 5-year survival rate vary from 48% to 90%.
Deciphera Pharmaceuticals is a biopharmaceutical company dedicated to discovering, developing, and delivering innovative cancer treatments. Leveraging its proprietary switch-control kinase inhibitor platform and extensive expertise in kinase biology, the company is advancing a diverse portfolio of groundbreaking medicines. One of their key products is RIPRETINIB, a switch-control inhibitor designed for fourth-line GIST treatment. RIPRETINIB has received regulatory approval in various countries, including Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States.
Resource: Genesis Pharma, January 09, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
